<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Avolio AW</submitter><funding>Ministero della Salute</funding><pagination>645-664</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12226705</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>77(3)</volume><pubmed_abstract>More liver transplants (LT) are performed worldwide thanks to extended criteria donors (ECD). This is paralleled by a supposed increased risk of allograft failure (AF) at 90 and 365 days. This study has been designed to portray the LT practice worldwide and investigate models of AF prediction and the impact of risk mitigation strategies for further improving graft and patient outcomes. This is a multicenter, international, non-competitive, observational two segment study on consecutive LTs over two periods (2017-2019 and 2022-2024). A steering committee of LT experts defined the study protocol. The prospective segment will enroll 750 patients from 15 high-volume LT centers (50 per center), and the retrospective segment will enrol 4200 patients from 56 LT centers (75 per center). To provide</pubmed_abstract><journal>Updates in surgery</journal><pubmed_title>Protocol for an international multicenter, prospective, observational, non-competitive, study to validate and optimise prediction models of 90-day and 1-year allograft failure after liver transplantation: The global IMPROVEMENT Study.</pubmed_title><pmcid>PMC12226705</pmcid><funding_grant_id>RF-2021-12372422</funding_grant_id><pubmed_authors>Burra P</pubmed_authors><pubmed_authors>Braun F</pubmed_authors><pubmed_authors>Junrungsee S</pubmed_authors><pubmed_authors>Ito T</pubmed_authors><pubmed_authors>Guo Z</pubmed_authors><pubmed_authors>Quintini C</pubmed_authors><pubmed_authors>Hu Z</pubmed_authors><pubmed_authors>De Santibanes M</pubmed_authors><pubmed_authors>Perini MV</pubmed_authors><pubmed_authors>and the global IMPROVEMENT study group</pubmed_authors><pubmed_authors>Feiwen D</pubmed_authors><pubmed_authors>Tandoi F</pubmed_authors><pubmed_authors>Cillo U</pubmed_authors><pubmed_authors>Egawa H</pubmed_authors><pubmed_authors>Tisone G</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Ciccarelli O</pubmed_authors><pubmed_authors>Subhash G</pubmed_authors><pubmed_authors>Boin I</pubmed_authors><pubmed_authors>Oniscu G</pubmed_authors><pubmed_authors>Wiederkehr J</pubmed_authors><pubmed_authors>Lesurtel M</pubmed_authors><pubmed_authors>Pasciuto T</pubmed_authors><pubmed_authors>Rela M</pubmed_authors><pubmed_authors>Patel M</pubmed_authors><pubmed_authors>Hammond J</pubmed_authors><pubmed_authors>Monakhov A</pubmed_authors><pubmed_authors>Noonthasoot B</pubmed_authors><pubmed_authors>Agopian V</pubmed_authors><pubmed_authors>Perera T</pubmed_authors><pubmed_authors>Caccamo L</pubmed_authors><pubmed_authors>Mazzaferro V</pubmed_authors><pubmed_authors>De Carlis L</pubmed_authors><pubmed_authors>Nadalin S</pubmed_authors><pubmed_authors>Giannarelli D</pubmed_authors><pubmed_authors>Romagnoli R</pubmed_authors><pubmed_authors>Salame E</pubmed_authors><pubmed_authors>Di Benedetto F</pubmed_authors><pubmed_authors>Cescon M</pubmed_authors><pubmed_authors>Grat M</pubmed_authors><pubmed_authors>Testa G</pubmed_authors><pubmed_authors>Garcia-Guix M</pubmed_authors><pubmed_authors>Gastaca M</pubmed_authors><pubmed_authors>Maluf D</pubmed_authors><pubmed_authors>Gruttadauria S</pubmed_authors><pubmed_authors>Vivarelli M</pubmed_authors><pubmed_authors>Mejia G</pubmed_authors><pubmed_authors>Ekser B</pubmed_authors><pubmed_authors>Mabrut JY</pubmed_authors><pubmed_authors>Nghia NQ</pubmed_authors><pubmed_authors>Spoletini G</pubmed_authors><pubmed_authors>Carraro A</pubmed_authors><pubmed_authors>Pulitano C</pubmed_authors><pubmed_authors>Vennarecci G</pubmed_authors><pubmed_authors>Croome K</pubmed_authors><pubmed_authors>Camagni S</pubmed_authors><pubmed_authors>Sudhindran S</pubmed_authors><pubmed_authors>Ghinolfi D</pubmed_authors><pubmed_authors>Martins PN</pubmed_authors><pubmed_authors>Ettorre GM</pubmed_authors><pubmed_authors>Nguyen BM</pubmed_authors><pubmed_authors>Taner T</pubmed_authors><pubmed_authors>Pascale MM</pubmed_authors><pubmed_authors>Pravisani R</pubmed_authors><pubmed_authors>Balci D</pubmed_authors><pubmed_authors>Lai Q</pubmed_authors><pubmed_authors>Avolio AW</pubmed_authors><pubmed_authors>Polak WG</pubmed_authors><pubmed_authors>Sapisochin G</pubmed_authors><pubmed_authors>Leipnitz I</pubmed_authors></additional><is_claimable>false</is_claimable><name>Protocol for an international multicenter, prospective, observational, non-competitive, study to validate and optimise prediction models of 90-day and 1-year allograft failure after liver transplantation: The global IMPROVEMENT Study.</name><description>More liver transplants (LT) are performed worldwide thanks to extended criteria donors (ECD). This is paralleled by a supposed increased risk of allograft failure (AF) at 90 and 365 days. This study has been designed to portray the LT practice worldwide and investigate models of AF prediction and the impact of risk mitigation strategies for further improving graft and patient outcomes. This is a multicenter, international, non-competitive, observational two segment study on consecutive LTs over two periods (2017-2019 and 2022-2024). A steering committee of LT experts defined the study protocol. The prospective segment will enroll 750 patients from 15 high-volume LT centers (50 per center), and the retrospective segment will enrol 4200 patients from 56 LT centers (75 per center). To provide</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2026-06-02T08:44:50.14Z</modification><creation>2026-04-16T03:12:49.631Z</creation></dates><accession>S-EPMC12226705</accession><cross_references><pubmed>40146444</pubmed><doi>10.1007/s13304-025-02078-4</doi></cross_references></HashMap>